Glucagon Use in Colonoscopies

Completed · Phase 4 · Has a placebo group

Conditions studied: Colon Cancer

In brief

The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.

Key facts

Study ID

NCT02078726

Run by

University of California, San Francisco

People needed

100

Starts

2014-04-01

Expected to finish

2018-05-01

Last updated by the study team

2025-07-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center.

You may not qualify if…

• Refusal to give informed consent.
• Age <18 or >70.
• Prior intra-abdominal surgery
• Diabetes
• Pheochromocytoma
• Insulinoma
• Liver disease (Child-Pugh Score >6)
• Pregnancy

Where it is running

• San Francisco General Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.